Tilapertin (INN), also known as AMG-747,[1] is a investigational drug which was being evaluated as an antipsychotic.

[2] Tilapertin appears to act via the blocking of the type 1 glycine transporter,[3] making it a glycine re-uptake inhibitor.

Two studies have been made in order to determine the safety of tilapertin and its potential as an add-on to anti-psychotic therapy in people with schizophrenia.

These studies were later halted due to a case of Stevens–Johnson syndrome in one of the participants.

[3] This drug article relating to the nervous system is a stub.